Improving treatment of subclinical cow mastitis using miramistin antiseptic agent

0Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The milk from cows suffering from mastitis often contains pathogenic and potentially pathogenic microflora, which presents a serious social and economic problem. Bacteriological and mycological examination at a dairy plant in Voronezhskaya oblast in the Russian Federation allowed diagnosing 37.3% of cows at the end of the lactation period with subclinical mastitis, which is due to the association of potentially pathogenic microorganisms with low sensitivity to a number of antibiotics. It was found that dienomast and the 0.01% solution of miramistin have the same therapeutical compatibility rate when introduced intracisternally before the drying off (93.3%). However, miramistin shows a better effect in the long term, i.e. after calving (by 15.5%). It was first ascertained that the combined use of both agents allows improving the preventive treatment of subclinical mastitis while maintaining up to 95.6% of the therapeutic effect after calving, which is better than when using each of the agents separately by 7.6% and 33.1% respectively. The intracisternally introduced miramistin ejects from the body together with milk within 24 hours.

Cite

CITATION STYLE

APA

Skogoreva, A. M., Manzhurina, O. A., Popova, O. V., Semyonov, S. N., & Aristov, A. V. (2020). Improving treatment of subclinical cow mastitis using miramistin antiseptic agent. In IOP Conference Series: Earth and Environmental Science (Vol. 422). Institute of Physics Publishing. https://doi.org/10.1088/1755-1315/422/1/012045

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free